Free Newsletter
FDA joins Tox21 collaboration
The FDA has signed on with the Tox21 collaboration. The regulator joins the EPA, the National Institute of Environmental Health Sciences National Toxicology Program, and the National Institute of Health Chemical Genomics Center in developing models to predict how chemicals will affect human health and the environment. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: